New study tracks hidden sugar damage in patients on IV nutrition
NCT ID NCT07392801
First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This observational study will follow 50 adults and children who are starting long-term parenteral nutrition (IV nutrition) to measure the buildup of advanced glycation end-products (AGEs) in their skin. AGEs are harmful compounds that form when sugar binds with proteins, and they may increase with IV nutrition. Researchers will use a non-invasive skin device to track AGE levels over 12 months, along with diet and metabolic tests, to understand risk factors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients (adults and children, all ages) initiating long-term parenteral nutrition * Followed at CHU de Bordeaux or Robert Debré Hospital (APHP) * Covered by French Social Security system * Written informed consent obtained from patient (if adult) or legal guardian (if minor) Exclusion Criteria: * Fitzpatrick skin type ≥ V (darker skin tones) * Forearm tattoos at the site of measurement * For patients included under 1 year of age: patients born prematurely (before 37 weeks of amenorrhea) * Pregnant or breastfeeding women.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced glycation and products are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
AP-HP - Hopital Robert Debré
NOT_YET_RECRUITINGParis, 75935, France
-
CHU de Bordeaux - Hôpital Haut Lévêque
RECRUITINGPessac, 33600, France
-
CHU de Bordeaux-Hôpital des enfants GH Pellegrin
NOT_YET_RECRUITINGBordeaux, 33076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.